Commercial Operations Optimization
MedTech commercial operations often evolve organically, creating complexity that hampers growth. Sales processes, distributor management, customer service, and field operations accumulate layers of inefficiency as companies scale from startup to mid-market. Dr. Kurr applies the same operating model discipline that transformed large pharma operations to MedTech - identifying process bottlenecks, redesigning workflows, and implementing scalable service delivery models. The key difference is pace: MedTech transformations must move faster, with less organizational inertia but also fewer resources to absorb transition costs.
Digital Health Strategy
Digital health is reshaping the MedTech landscape - from connected devices and remote monitoring to AI-powered diagnostics and digital therapeutics. But technology alone does not create value. Dr. Kurr helps MedTech companies develop digital health strategies that connect technology capabilities to commercial outcomes: which digital features drive adoption, how to position digital solutions for reimbursement, and how to build the operational infrastructure to support digital-physical hybrid products. His work at THENA Capital provides insight into what investors look for in digital health companies, informing strategy from both the operator and investor perspectives.
Device Company Scaling
Scaling a device company from early-stage to commercial success requires navigating regulatory approvals, building manufacturing and supply chain capabilities, establishing distribution networks, and building a commercial organization - often simultaneously. Dr. Kurr's fractional C-level model provides the executive bandwidth needed during this critical phase. His experience building organizations from scratch at Boehringer Ingelheim translates directly to the device company context: the same principles of structure follows process follows strategy apply, adapted to the faster timelines and leaner resources of the MedTech sector.
Market Access and Reimbursement
Reimbursement is the single most important commercial lever for many MedTech and diagnostics companies. Without a clear pathway to reimbursement, even breakthrough technologies fail commercially. Dr. Kurr helps companies develop market access strategies that begin early - during product development - and integrate health economics, clinical evidence generation, and payer engagement into the overall commercial strategy. His cross-industry experience ensures that market access is not treated as a standalone function but as an integral part of the go-to-market model.